CYSTAMINE INHIBITS HIV TYPE-1 REPLICATION IN CELLS OF MONOCYTE-MACROPHAGE AND T-CELL LINEAGES

The effects of cysteamine (2-aminoethanethiol, MEA) and its disulfide, cystamine, on the human immunodeficiency virus (HIV-1) expression in chronically infected promonocytic cells (U1), T cell line (ACH-2), and peripheral blood monocyte-derived macrophages (MDM) were investigated , U1 and ACH-2 cells constitutively express low levels of virus, which is increased by the addition of tumor necrosis factor (TNF-alpha), in terleukin 6 (IL-6), granulocyte-macrophage-colony-stimulating factor ( GM-CSF), and other inducers, Cystamine, in noncytotoxic doses, suppres sed in a concentration-dependent fashion the induction of HIV-1 expres sion mediated by TNF-alpha, IL-6, GM-CSF, and monokine-enriched monocy te culture supernatants in both U1 and ACH-2 cells as determined by HI V-1 reverse transcriptase (RT) activity, Similarly, HIV-1 expression w as substantially reduced in the cystamine-treated primary MDM cultures compared with the untreated control cultures, The addition of cystami ne into HIV-1 chronically infected MDM (12 days after infection was es tablished) also suppressed 80-90% of RT activity in comparison to the untreated controls; HIV-1 (Bal) infected MDM cultures (without cystami ne treatment) demonstrated giant syncytium formation, whereas cystamin e-treated cultures lacked the giant syncytia induced by HIV-1 infectio n, Cystamine also inhibited LPS-induced TNF production in MDM, In cont rast to cystamine, cysteamine showed no significant effects on either the monokine-induced HIV-1 expression in U1 or ACH-2 or acute and chro nic HIV-1 infection in MDM, Thus, these observations indicate that cys tamine may have the potential to limit HIV-1 replication in T cells an d MDM in vivo and may be a member of new class of drugs with anti-HIV- 1 effects.